Novartis Invests $23 Billion in US Expansion with New San Diego Research Hub
Pharmaceutical giant Novartis has broken ground on a cutting-edge biomedical research center in San Diego, California, marking a significant step in its ambitious $23 billion investment plan across the United States.
Novartis has commenced construction on its new global biomedical research centre in San Diego, California, aimed at expanding its drug discovery capabilities. The 466,000ft² facility, slated to open in 2029, will house approximately 1,000 employees and serve as a pivotal location for end-to-end drug discovery efforts.
The new center is strategically designed to integrate with Novartis’ existing global research network, fostering collaboration with locations in Basel, Switzerland, and Cambridge, Massachusetts. This interconnected approach aims to streamline drug discovery activities across different regions and accelerate the development of innovative therapies.
Expanding Therapeutic Focus
The San Diego facility will concentrate on a broad spectrum of therapeutic areas, including oncology, neuroscience, age-related diseases, global health, and regenerative medicine. Researchers will also focus on advancing expertise in emerging fields such as gene and cell therapies, RNA-based therapies, biologics, targeted protein degradation, and novel drug delivery systems.
According to a company release, the center will leverage advanced artificial intelligence (AI) and computational technologies to enhance its research capabilities and facilitate the sharing of insights and innovations. This integration of technology is expected to significantly accelerate the drug discovery process.
Part of a Larger US Investment
The San Diego research center represents a key component of Novartis’ broader $23 billion investment in the US. This investment also encompasses a manufacturing hub in North Carolina, a radioligand therapy (RLT) manufacturing site in Carlsbad, California, expansions in Indiana and New Jersey, and planned RLT facilities in Texas and Florida. In January 2026, Novartis plans to construct an RLT manufacturing facility in Winter Park, Florida, as part of its ongoing radioligand therapy manufacturing expansion.
Accelerating Pipeline from Discovery to Patients
Fiona Marshall, president of Novartis biomedical research, emphasized the strategic importance of the new center. “This new research centre will strengthen our scientific leadership and accelerate the discovery of transformative medicines for patients worldwide, while deepening our connectivity with biotech, academic and technology partners across the region,” she stated. “Designed to power future drug discovery, with a focus on genetics and human biology in key therapeutic areas such as neuroscience and oncology, it will create a single Novartis research centre within one of the world’s premier life sciences ecosystems—accelerating our pipeline from discovery to patients.”
The investment underscores Novartis’ commitment to innovation and its dedication to addressing unmet medical needs through cutting-edge research and development.
